ImmuPharma (LON:IMM) Trading Down 6.8% - Here's What Happened

Key Points

• ImmuPharma plc shares fell 6.8% to GBX 16.40 ($0.22), significantly below their previous close of GBX 17.60 ($0.24), with trading volume seeing a notable increase of 165%.
• The company's PE ratio is listed at -1,696.63, reflecting a challenging financial situation, while analysts predict an EPS of -339.0000022 for the current fiscal year.
• ImmuPharma specializes in peptide-based therapeutics aimed at treating autoimmune diseases, with its lead program being Lupuzor™, an innovative treatment for Lupus.

Shares of ImmuPharma plc (LON:IMM - Get Free Report) were down 6.8% during mid-day trading on Tuesday . The stock traded as low as GBX 14.10 ($0.19) and last traded at GBX 16.40 ($0.22). Approximately 22,083,545 shares were traded during mid-day trading, an increase of 165% from the average daily volume of 8,347,389 shares. The stock had previously closed at GBX 17.60 ($0.24).

ImmuPharma Stock Down 14.2%

The company's fifty day moving average is GBX 3.43 and its 200-day moving average is GBX 3.01. The company has a market cap of £75.46 million, a PE ratio of -1,696.63 and a beta of 1.53.

ImmuPharma (LON:IMM - Get Free Report) last released its quarterly earnings results on Wednesday, August 6th. The company reported GBX (0.38) earnings per share for the quarter. ImmuPharma had a negative return on equity of 131.41% and a net margin of 3,519.56%. Equities research analysts expect that ImmuPharma plc will post -339.0000022 EPS for the current fiscal year.

ImmuPharma Company Profile

ImmuPharma PLC LSE AIM: IMM is a specialty biopharmaceutical company that discovers and develops peptide-based therapeutics. The Company's portfolio includes novel peptide therapeutics for autoimmune diseases and anti-infectives. The lead program, P140 (Lupuzor™), is a first-in class autophagy immunomodulator for the treatment of Lupus and preclinical analysis suggest therapeutic activity for many other autoimmune diseases that share the same autophagy mechanism of action.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.